BioTime, Inc. Share Price NYSE
Stocks
US09066L1052
Biotechnology & Medical Research
| Market Cap | 255M 223M 210M 191M 358M 24.47B 359M 2.51B 968M 12.47B 959M 938M 40.23B | P/E 2026 * |
-15x | P/E 2027 * | -9.68x |
|---|---|---|---|---|---|
| Enterprise Value | 255M 223M 210M 191M 358M 24.47B 359M 2.51B 968M 12.47B 959M 938M 40.23B | EV / Sales 2026 * |
16.8x | EV / Sales 2027 * | 15.2x |
| Free-Float |
95.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioTime, Inc.
| 1 day | +7.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 16/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 13/11/2022 |
Priyantha Herath
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 30/06/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 10/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 26/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.37% | -11.55% | - | - | 255M | |
| +1.79% | +3.83% | +3.14% | +30.85% | 46.68B | |
| +1.30% | +1.58% | +44.15% | +35.50% | 44.42B | |
| +0.95% | -6.02% | +342.72% | +532.41% | 41.32B | |
| +4.23% | +3.35% | +9.35% | +94.73% | 41.58B | |
| +1.11% | +1.45% | +11.52% | +45.96% | 30.14B | |
| +1.94% | +4.84% | +25.19% | +159.21% | 17.42B | |
| +0.37% | -10.32% | - | - | 15.6B | |
| +0.85% | +7.10% | +25.56% | +43.46% | 15.54B | |
| +0.24% | +25.43% | -11.57% | - | 14.08B | |
| Average | +1.49% | +3.55% | +56.26% | +134.59% | 29.64B | |
| Weighted average by Cap. | +0.89% | +2.11% | +70.38% | +142.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.19M 13.25M 12.48M 11.36M 21.3M 1.46B 21.33M 149M 57.59M 741M 57.07M 55.81M 2.39B | 16.83M 14.68M 13.82M 12.59M 23.6M 1.61B 23.63M 166M 63.81M 822M 63.24M 61.83M 2.65B |
| Net income | -22.64M -19.74M -18.59M -16.93M -31.75M -2.17B -31.78M -223M -85.82M -1.1B -85.04M -83.16M -3.57B | -34.44M -30.03M -28.28M -25.76M -48.29M -3.3B -48.35M -339M -131M -1.68B -129M -127M -5.42B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
